Jeffrey S. Parkin

Array ( [id] => 9895114 [patent_doc_number] => 20150050309 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-02-19 [patent_title] => 'VACCINE' [patent_app_type] => utility [patent_app_number] => 14/332562 [patent_app_country] => US [patent_app_date] => 2014-07-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 26 [patent_no_of_words] => 51544 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14332562 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9798650 [patent_doc_number] => 20150010594 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-01-08 [patent_title] => 'HIV VACCINE' [patent_app_type] => utility [patent_app_number] => 14/322545 [patent_app_country] => US [patent_app_date] => 2014-07-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 14634 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14322545 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10974226 [patent_doc_number] => 20140377259 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-12-25 [patent_title] => 'METHODS FOR INHIBITING HIV-1 REPLICATION INVOLVING THE ADMINISTRATION OF AN ANTI-CCR5 RECEPTOR MONOCLONAL ANTIBODY AND SMALL MOLECULE CCR5 RECEPTOR ANTAGONIST' [patent_app_type] => utility [patent_app_number] => 14/319505 [patent_app_country] => US [patent_app_date] => 2014-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 31847 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14319505 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13065441 [patent_doc_number] => 10053493 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-08-21 [patent_title] => Methods and compositions for dengue virus vaccines [patent_app_type] => utility [patent_app_number] => 14/392127 [patent_app_country] => US [patent_app_date] => 2014-06-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 9 [patent_no_of_words] => 11311 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14392127 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10761969 [patent_doc_number] => 20160108122 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-04-21 [patent_title] => 'THERAPEUTIC OR PROPHYLACTIC AGENT FOR IMMUNODEFICIENCY VIRUS INFECTION' [patent_app_type] => utility [patent_app_number] => 14/892892 [patent_app_country] => US [patent_app_date] => 2014-05-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 6439 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14892892 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10298836 [patent_doc_number] => 20150183834 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-07-02 [patent_title] => 'Filoviral Immunosuppressive Peptides' [patent_app_type] => utility [patent_app_number] => 14/266355 [patent_app_country] => US [patent_app_date] => 2014-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 29010 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14266355 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11612586 [patent_doc_number] => 09650435 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-05-16 [patent_title] => 'Monoclonal antibodies directed against a novel pathogenic west African human immunodeficiency virus type 2 (HIV-2) group F isolate' [patent_app_type] => utility [patent_app_number] => 14/263517 [patent_app_country] => US [patent_app_date] => 2014-04-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 9494 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14263517 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10769049 [patent_doc_number] => 20160115205 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-04-28 [patent_title] => 'POLYVALENT HIV-1 IMMUNOGEN' [patent_app_type] => utility [patent_app_number] => 14/784496 [patent_app_country] => US [patent_app_date] => 2014-04-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 4183 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14784496 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10760673 [patent_doc_number] => 20160106827 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-04-21 [patent_title] => 'V3 IMMUNOGENS' [patent_app_type] => utility [patent_app_number] => 14/784501 [patent_app_country] => US [patent_app_date] => 2014-04-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 14787 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14784501 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9785262 [patent_doc_number] => 20140302081 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-10-09 [patent_title] => 'HIV-1 GP120 MINI V3 LOOP AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 14/251070 [patent_app_country] => US [patent_app_date] => 2014-04-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 28253 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14251070 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9864151 [patent_doc_number] => 20150044170 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-02-12 [patent_title] => 'EXPRESSION OF VIRUS ENTRY INHIBITORS AND RECOMBINANT AAV THEREFOR' [patent_app_type] => utility [patent_app_number] => 14/248839 [patent_app_country] => US [patent_app_date] => 2014-04-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 8254 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14248839 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9719744 [patent_doc_number] => 20140255444 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-09-11 [patent_title] => 'COMPOSITIONS AND METHODS FOR TREATING EBOLA VIRUS INFECTION' [patent_app_type] => utility [patent_app_number] => 14/243518 [patent_app_country] => US [patent_app_date] => 2014-04-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 7248 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14243518 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13946983 [patent_doc_number] => 10209257 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-02-19 [patent_title] => Solid support comprising HIV-1 clade C envelope peptides for the detection of HIV-1-specific antibodies [patent_app_type] => utility [patent_app_number] => 14/775813 [patent_app_country] => US [patent_app_date] => 2014-03-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 11 [patent_no_of_words] => 10898 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14775813 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10693758 [patent_doc_number] => 20160039904 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-02-11 [patent_title] => 'STABILIZED SINGLE HUMAN CD4 DOMAINS AND FUSION PROTEINS' [patent_app_type] => utility [patent_app_number] => 14/777245 [patent_app_country] => US [patent_app_date] => 2014-03-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 13385 [patent_no_of_claims] => 40 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14777245 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9720882 [patent_doc_number] => 20140256583 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-09-11 [patent_title] => 'DETECTION OF HUMAN ENDOGENOUS RETROVIRUS EXPRESSION IN CANCER AND NORMAL CELLS' [patent_app_type] => utility [patent_app_number] => 14/198201 [patent_app_country] => US [patent_app_date] => 2014-03-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 13569 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14198201 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14296981 [patent_doc_number] => 10288613 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-05-14 [patent_title] => Method for detecting HIV-1 co-receptor tropism [patent_app_type] => utility [patent_app_number] => 14/195528 [patent_app_country] => US [patent_app_date] => 2014-03-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 13 [patent_no_of_words] => 15242 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 332 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14195528 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9545525 [patent_doc_number] => 20140170172 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-06-19 [patent_title] => 'Tat-Based Tolerogen Compositions and Methods for Making and Using Same' [patent_app_type] => utility [patent_app_number] => 14/187678 [patent_app_country] => US [patent_app_date] => 2014-02-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 11511 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14187678 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9546060 [patent_doc_number] => 20140170709 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-06-19 [patent_title] => 'VECTOR FOR GENE THERAPY' [patent_app_type] => utility [patent_app_number] => 14/169361 [patent_app_country] => US [patent_app_date] => 2014-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 10178 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14169361 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12286144 [patent_doc_number] => 09932370 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-04-03 [patent_title] => Stabilized mosaic human immunodeficiency virus type 1 (HIV-1) GP140 envelope (ENV) trimers [patent_app_type] => utility [patent_app_number] => 14/149549 [patent_app_country] => US [patent_app_date] => 2014-01-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 17322 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14149549 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9641949 [patent_doc_number] => 20140220060 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-08-07 [patent_title] => 'HIV-1 SOUTH AFRICAN SUBTYPE C ENV PROTEINS' [patent_app_type] => utility [patent_app_number] => 14/141396 [patent_app_country] => US [patent_app_date] => 2013-12-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 160 [patent_figures_cnt] => 160 [patent_no_of_words] => 45595 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14141396 [rel_patent_id] =>[rel_patent_doc_number] =>)